Covid-19 vaccine, which has attracted much attention, was launched in China!
On February 19, the joint prevention and control mechanism of the State Council held a press conference. Wu Liangyou, deputy director of the disease control bureau of the National Health Commission, introduced that according to the progress of covid-19 virus vaccine research and development, it was decided to further supplement and improve the covid-19 virus vaccine immunization strategy. Recently, with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy sequential immunization.
Covid-19 vaccine “mixed” will undoubtedly have an impact on the current vaccination pattern. An enterprise personage who asked not to be named told reporters that the “mixed fight” will improve the market space and profitability of relevant enterprises.
However, Shi lichen, a medical strategic marketing expert, told the Securities Daily that the covid-19 epidemic is still spreading, and the future market space of “mixed hit” vaccine is not only in China, but also exported overseas.
covid-19 vaccine sequential enhancement approved
The research data show that homologous booster immunization and sequential booster immunization can further improve the immune effect.
” all vaccinated with inactivated vaccines of Sinopharm Zhongsheng Beijing company, Wuhan company, Beijing Kexing company and Tianjin Cansino Biologics Inc(688185) ” The company’s adenovirus vector vaccine can enhance the immunity of target people over the age of 18 after 6 months, that is, it can be strengthened with the original vaccine. After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of vaccination with the above three inactivated vaccines can also choose the recombinant protein vaccine of zhifeilongke horse or Cansino Biologics Inc(688185) adenovirus vector vaccine for sequential booster immunization. “Wu Liangyou said that for the target population, choose one of homologous enhanced immunization and sequential enhanced immunization.
In addition, the joint prevention and control mechanism of the State Council also approved the homologous enhanced immunization of covid-19 virus inactivated vaccine of Shenzhen Kangtai company and the Institute of biology of the medical college.
At present, most people in China are vaccinated with two doses of inactivated vaccine. Since the launch of covid-19 vaccine intensive vaccination, the public can only choose homologous vaccination, that is, continue to vaccinate inactivated vaccine. Then, after the sequential reinforcement is approved, how many kinds of play methods does the reinforcement needle have now?
” there are two options. One is the same technical route to strengthen vaccination, which we call homologous enhancement. The other refers to the alternative vaccination of vaccines from different technical routes, which we call sequential enhancement. To put it simply, two doses of inactivated vaccine were given before, and the booster injection was still given inactivated vaccine, which belongs to homologous enhancement; If the previous two doses of inactivated vaccine, enhanced injection of adenovirus vector covid-19 vaccine or recombinant protein vaccine, it belongs to sequential enhancement. ” A vaccine enterprise related person introduced to our reporter.
Zheng Zhongwei, leader of the vaccine research and development team of the scientific research group of the joint prevention and control mechanism of the State Council, said in an interview: ” through the strengthening of sequential immunization, the antibody level will be further improved “.
The information obtained by the reporter from Cansino Biologics Inc(688185) company shows that the results of the sequential booster immunization clinical trial carried out by the team of Jiangsu Provincial Center for Disease Control and prevention show that the level of neutralizing antibody is five times higher than that of inactivated vaccine when using inactivated vaccine for basic immunization and Cansino Biologics Inc(688185) biological adenovirus vector covid-19 vaccine for sequential booster. After two doses of inactivated vaccine, one dose of Cansino Biologics Inc(688185) biological adenovirus vector covid-19 vaccine was inoculated as reinforcement. After 14 days, the neutralizing antibody level was 197.4 (95% ci167.7232.4).
enterprises strengthen sequential vaccine research and development
At present, the epidemic prevention and control task of “external defense input and internal defense rebound” in China is still arduous. Wang Huaqing, chief expert of immunization planning of China CDC, introduced that based on research evidence, sequential immunization has been implemented in the Americas, whether in South America or North America, as well as some countries in Europe and Southeast Asia.
the World Health Organization supports flexible homologous and heterologous vaccination programmes. of course, for countries considering heterologous vaccination scheme, the World Health Organization recommends covid-19 virus vaccine with different technical route from the first dose for subsequent dose vaccination based on the background that heterologous vaccination and homologous vaccination have the same or higher immunogenicity or effectiveness and vaccine accessibility.
According to LSHTM tracker information, as of February 7, 2022, a total of 121 covid-19 vaccine products around the world were in clinical trials, of which 27 products had been approved for marketing or emergency use. China has obtained conditional approval for listing 4 products (products without recombinant protein technology route), obtained emergency use approval for 7 products (including 1 recombinant protein technology route), and a total of 21 products are in clinical trial stage (8 recombinant protein technology routes).
it is worth mentioning that in addition to Cansino Biologics Inc(688185) and Chongqing Zhifei Biological Products Co.Ltd(300122) , other Chinese enterprises are also carrying out sequential strengthening of vaccine research and development.
In February 17th, Livzon Pharmaceutical Group Inc(000513) released the “recombinant New Coronavirus fusion protein vaccine V-01” (hereinafter referred to as V-01) developed by the controlling subsidiary, Zhuhai Li Zhu mAb Biotechnology Co., Ltd. (hereinafter referred to as “Li Zhu monoclonal antibody”), which has completed the medium term principal data analysis of the sequential strengthening phase III clinical trial.
According to the analysis of the present stage, the results showed that the annual incidence rate of V-01 sequential enhancement and two needle inactivated vaccine was 6.73% and 12.80%, respectively, with significant difference between the V-01 sequential and two needle inactivated vaccine groups (P=0.0012). The absolute protective force of v-01 after sequential strengthening is 61.35%, which has significant strong and excellent effect. V-01 sequential strengthening of absolute protection has met who standards
